Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.
about
Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicansAntifungal resistance in pathogenic fungiCandida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug actionPotent synergism of the combination of fluconazole and cyclosporine in Candida albicansDouble-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patientsIn vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virusIn vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeastsIn vitro and in vivo antifungal activities of D0870, a new triazole agentIn vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis speciesComparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assaysIn vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida speciesSensitivity of clinical isolates of Candida to essential oils from Burseraceae familyEpidemiology of invasive candidiasis: a persistent public health problemHistory of medical mycology in the united states.New and emerging yeast pathogensInternational surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY ParCandida pseudorugosa sp. nov., a novel yeast species from sputum.Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients.A cluster of Candida krusei infections in a haematological unit.Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.Antifungal and antiviral agents: a review.The ins and outs of DNA fingerprinting the infectious fungiNosocomial Candida glabrata colonization: an epidemiologic study.Panfungal PCR assay for detection of fungal infection in human blood specimens.Constant low rate of fungemia in norway, 1991 to 1996. The Norwegian Yeast Study Group.Efficacy of API 20C and ID 32C systems for identification of common and rare clinical yeast isolates.Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center.Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensisRapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR.Mechanism of fluconazole resistance in Candida krusei.Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.Role of newer azoles in surgical patients.Rapid identification of up to three Candida species in a single reaction tube by a 5' exonuclease assay using fluorescent DNA probes.Identification of Candida dubliniensis in a prospective study of patients in the United States.Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital.Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.Experimental oral candidiasis in animal models.Antifungal resistance in yeast vaginitis.
P2860
Q24550731-64777750-6604-41F3-BAC8-77F16800638FQ28208165-C0B37A1E-BC24-4CB5-8DF6-13DD8E3FF7C3Q28260910-5F53BE92-8531-4470-9827-D22D490C3ED4Q28343624-624DF909-52F3-4444-84AF-63E13EB2B0EDQ28344597-E90A34EA-637B-46BC-8A11-364E31F9890CQ28362691-E40A0FA3-8003-4444-B9CE-E17DFBAF976AQ28368500-3B71A58A-F309-4024-B1BE-B4C4713D3216Q28378400-D6565B52-E341-4071-AB6F-A6E42A2A680BQ28378447-396FF5C4-7D27-4DDD-BC31-4C12FA19921CQ28378793-32E9DB56-346C-4C84-89CD-710FC709D3F4Q28378998-46E4D7AB-4136-4727-9AE5-EE573EFF8E60Q28379025-9D75B733-1FE3-42C3-93BF-559A63EAFCDDQ28830247-B6534B80-FC6E-40D1-AE3E-0E9DCC97C17AQ29616758-3CC41B8F-60A3-4159-BF10-3233B1171FBEQ30452877-CD91B979-D8EF-43D9-B3CF-B01761E0D2FEQ30452880-1D779343-39A8-40F3-9B89-2BF9404DBBCBQ30453440-F162FF40-D3FE-4729-A9CE-840D72E97623Q31064491-66AFCAEA-BD79-4F84-80F9-E40CDFFF7BC5Q31372000-AD90CFE9-25DB-4DFE-ABF5-73040E299882Q31893406-1CA98F24-07F7-4DB2-9A1C-2F97D8CB4297Q33294780-A6B22E15-D7A5-40CB-AD35-3E469EFFFEF7Q33340528-1168AC3E-7136-43CF-9248-CCD9DEC11F47Q33539956-0605E972-31C8-442B-9240-0C92C14D95D5Q33555593-B4856D06-D7BC-467F-A0C2-CDAE97656A1BQ33656028-771974F3-ED5C-4DB3-8BF3-0D31DF99B18BQ33665050-3B0B958C-625B-493E-9058-FD5362482797Q33684486-2AC7CA35-33CB-402C-8BA2-ECDB6F23301AQ33688448-F5D70375-19AC-44CC-B8EB-AF8CAE10A3F1Q33691981-738D9EA3-BC60-439B-8BCD-E987C524347DQ33694469-CA77E585-B42C-4FBA-BF72-F5FAC44288D8Q33699122-6771B238-FB18-40C7-BFF6-A6B60B15098FQ33699487-71436EA7-4032-4329-A4D8-63958A26CD14Q33721804-A452EC63-8F51-4343-B759-21420A252F79Q33840089-ADD178F3-CADE-4A1B-A0A6-DACA1A022F21Q33958156-47C45BA5-A0A8-48C1-9441-D3DA3CAD24A7Q33958617-E595FE5D-91D6-457D-8D76-271EAFA2F3CBQ33959121-8DFFCB4A-7C66-435C-8013-241EA0412F80Q33972828-56F0587E-DD9E-4EC0-8FFA-B3445CCAEA13Q33975696-A1A874A1-0144-4B4C-970B-1BA8B7ABC635Q33977460-284940BA-A30C-4915-9F85-A6403642A8D2
P2860
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Increase in Candida krusei inf ...... hylactically with fluconazole.
@en
Increase in Candida krusei inf ...... hylactically with fluconazole.
@nl
type
label
Increase in Candida krusei inf ...... hylactically with fluconazole.
@en
Increase in Candida krusei inf ...... hylactically with fluconazole.
@nl
prefLabel
Increase in Candida krusei inf ...... hylactically with fluconazole.
@en
Increase in Candida krusei inf ...... hylactically with fluconazole.
@nl
P2093
P1476
Increase in Candida krusei inf ...... hylactically with fluconazole.
@en
P2093
P304
P356
10.1056/NEJM199110313251803
P407
P577
1991-10-01T00:00:00Z